Published News

Global Psychedelic therapeutics market is estimated to be worth over USD 6.5 billion in 2030, predicts Roots Analysis

https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

A growing body of evidence suggests that using psychedelics, such as psilocybin and LSD, in combination with psychotherapy, can treat the symptoms of several mental health conditions, including depression and substance use disorders Roots Analysis has announced the addition of “Global Psychedelic Therapeutics Market, 2020-2030” report to its list of offerings. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of drug developers engaged in the development of psychedelic therapeutics.  Tabulated profiles of prominent psychedelic therapeutics developers. shortlisted on the basis of the number of pipeline products).  Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis having two or more psychedelics-based therapies in phase II clinical studies and above).  An insightful analysis of clinical trial sites where the studies have been / are being conducted for evaluation of various psychedelic therapeutics.  A list of key opinion leaders (KOLs) within this domain, and detailed 2×2 matrices to assess the relative experience of key individuals who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.  A detailed analysis of nearly 545 grants that have been awarded to research institutes engaged in psychedelic therapeutics projects, in the period between 2015 and 2020 (till May).  An analysis of the partnerships that have been established in the recent past (2017-2020 till May),  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2017-2020.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Target Disease Indication  Anxiety and Depression  Trauma  Pain Disorder  Sleep related Disorder  Origin of Psychedelic Substance  Natural  Synthetic  Type of Psychedelic Substance  Gamma-hydroxybutyrate  Ketamine  MDMA  Psilocybin  Route of Administration  Oral  Intranasal  Sublingual  Key Geographies  North America  Europe  Asia-Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companies  Andrew Chadeayne (Founder & Chief Executive Officer, CaaMTech)  Janakan Krishnarajah (Chief Operating Officer and Chief Medical Officer, iX Biopharma)  Alexander Speiser (Chief Operating Officer, Orthogonal Thinker)  Tracy Cheung, (Chief Communications Officer, COMPASS Pathways) Key companies covered in the report  Celon Pharma  iX Biopharma  MAPS Public Benefit  MindMed  Janssen Pharmaceuticals  Jazz Pharmaceutical For additional details, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html or email [email protected] You may also be interested in the following titles: 1. Endocannabinoid System Targeted Therapeutics Market, 2020-2030 2. Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019 3. Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights 4. Neoantigen Targeted Therapies Market, 2019-2030 5. Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis

The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis

https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research London Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings. Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html Key Market Insights Over 170 RNAi therapeutics are currently under development Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell. More than 70% of ongoing clinical trials are being conducted in North America and Europe In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs. Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014 Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (58%). USD 5.4+ billion invested by both private and public investors, since 2014 Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives. Around 65 partnerships were inked since 2014 Maximum number of deals were reported in 2018. Around 30% of the deals were related to the R&D agreements; this was followed by technology licensing agreements (27%). RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030 This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/278/request-sample.html Key Questions Answered  Who are the leading industry players in this market?  What are the clinical conditions for which RNAi therapeutics are being developed?  Who are the key investors in the RNAi therapeutics market?  What kind of commercialization strategies are being adopted by RNAi therapeutics developers?  What are the different promotional and reimbursement strategies used for RNAi therapeutics?  What are the prevalent R&D trends related to RNAi therapeutics?  What are the various delivery / technology platforms that are being used for the development of RNAi therapeutics?  What kind of partnership models are used by stakeholders in this industry?  Who are the key service providers in this field of therapeutics?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:  Key therapeutic areas  Oncological disorders  Infectious diseases  Genetic disorders  Ophthalmic disorders  Hepatic disorders  Respiratory disorders  Type of RNAi molecule  siRNA  miRNA  shRNA  sshRNA  DNA  Route of administration  Subcutaneous  Intravenous  Intradermal  Intratumoral  Intravitreal  Oral  Intramuscular  Key geographical regions  North America  Europe  Asia Pacific and the Rest of the World  Leading Players The report features inputs from eminent industry stakeholder(s), according to whom RNAi therapeutics are promising domain of pharmaceutical industry. The report includes detailed transcripts of discussions held with the following expert(s):  Amotz Shemi (Chief Executive Officer, Silenseed) The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).  Quark Pharmaceuticals  Alnylam Pharmaceuticals  Dicerna Pharmaceuticals  Souzhou Ribo Life Sciences  Olix Pharmaceuticals  Sirnaomics  Ariz Precision Medicine  Arrowhead Pharmaceuticals  Gradalis  Benitec Biopharma For additional details, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html or email [email protected] You may also be interested in the following titles: 1. Gene Therapy Market (3rd Edition), 2019-2030 2. Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030 3. Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis

With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis

https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic. Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions  Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).  An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.  An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.  A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.  An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)  A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.  A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.  A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Source of Stem Cell  Allogeneic  Autologous  Origin of Stem Cell  Adult  Embryonic  Type of Stem Cell  Hematopoietic  Mesenchymal  Progenitor  Others  Lineage of Stem Cell  Adipose Tissue  Bone Marrow  Cord Blood  Others  Route of Administration  Intraarticular  Intracoronary  Intramuscular  Intramyocardial  Intrathecal  Intravenous  Surgical Implantations  Others  Therapeutic Area  Autoimmune / Inflammatory Disorder  Cardiovascular Disorders  Metabolic Disorder  Musculoskeletal Disorders  Oncological Disorders  Neurological Disorders  Ophthalmic Disorders  Others  End Users  Ambulatory Surgery Centers  Hospitals  Specialty Clinics  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World  Transcripts of interviews held with the following senior level representatives of stakeholder companies  William L Rust (Founder and Chief Executive Officer, Seraxis)  Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)  Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)  Kikuo Yasui (Director and Chief Operating Officer, Heartseed)  Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)  Gilles Devillers (President, Bio Elpida)  Fiona Bellot (Business Development Manager, Roslin Cell Therapies)  David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the report  Anterogen  Athersys  CHABiotech  Cytopeutics  Hope Biosciences  Japan Regenerative Medicine  Lineage Cell Therapeutics  Orchard Therapeutics  Osiris Therapeutics  Pluristem Therapeutics  Promithera Biosciences  Regenexx  Stempeutics Research  SCM Life Sciences  TICEBA For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent Offerings 1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030 2. Antibody Drug Conjugates Market (5th Edition), 2019-2030 3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis

Fortitude Valley Accommodation {4-Star} FV4006 Apartments in Brisbane

https://www.fv4006apartments.com.au/

4-star Perfect Holiday Accommodation Apartment in Fortitude Valley, Brisbane. Located 1.8 km from Queen Street Mall & 2 blocks away from Chinatown. We are a small family-owned business run by two sisters, one of which lives on site. Our number one focus is to give good customer service and to work with our tenants and guests to make our community an enjoyable place to live. We are in the process of improving and beautifying the facilities over the next year.

The peptides and macrocycle drug discovery services market is estimated to be worth USD 1.5 billion in 2030, predicts Roots Analysis

https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities. Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings. The report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes:  A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services  An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size).  An in-depth analysis of peptide platform and library service providers, featuring information on their company details, purpose of the platform, type of peptide manufactured and platform access model.  Profiles of peptides and macrocycle drug discovery service providers, featuring information on the year of establishment, location of headquarters, peptide discovery service / platform portfolio, recent developments, and an informed future outlook.  An analysis of the partnerships that have been established in the recent past, covering mergers and acquisitions, research collaborations, R&D agreements, licensing agreements (related to both technology platforms and service providers) and other form of collaborations.  An analysis of proprietary display technologies developed by different drug discovery technology providers, based on the 2X2 matrix.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of peptides  Synthetic peptides  Biologic and recombinant peptides  Type of discovery steps  Target identification and validation  Hit identification  Lead generation  Lead optimization  Therapeutic Area  Oncological disorders  Metabolic disorders  Cardiovascular disorders  Infectious diseases  Urological disorders  Endocrine disorders  CNS disorders  Other diseases  Company Size  Small companies  Mid-sized companies  Large and very large companies  Key geographical regions  Europe  North America  Asia-Pacific and the Rest of the World Key companies covered in the report  GenScript  JPT Peptide Technologies  CPC Scientific  IRBM  Creative Peptides  Pepscan  Interprotein  RA Pharmaceuticals  Pepticom  PeptiDream  Creative Biolabs  MeSCue-Janusys For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Other Recent Offerings 1. DNA-Encoded Libraries: Platforms and Services Market, 2020–2030 2. Antibody Contract Manufacturing Market, 2020 – 2030 3. Global Autoinjectors Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The novel vaccine delivery devices market is estimated to be worth USD 1.5 billion in 2030, predicts Roots Analysis

https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html

Owning to a variety of relevant reasons, which include trypanophobia and dependence on the cold chain, there is an evident demand for innovative and user-friendly vaccine delivery systems that are also safe and efficient Roots Analysis is pleased to announce the publication of its recent study, titled, “Novel Vaccine Delivery Devices Market, 2019-2030”. The report features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years. Amongst other elements, the report includes:  A detailed assessment of the overall novel vaccine delivery devices market landscape, featuring an elaborate list of device developers engaged in the development of novel vaccine delivery devices.  A detailed competitiveness analysis of novel vaccine delivery devices, taking into consideration the supplier power and key product specifications.  An analysis evaluating the effectiveness of various vaccines delivery devices in order to compare their respective strengths and capabilities based on a variety of parameters.  A detailed list of marketed and pipeline vaccine candidates that are anticipated to be developed in combination with novel vaccine delivery devices in the near future.  Elaborate profiles of prominent product developers engaged in the novel vaccine delivery devices domain (shortlisted on the basis of the number of pipeline products).  An analysis of the partnerships that have been established in this domain, in the recent past.  A discussion on important, industry-specific trends, key market drivers and challenges, under a comprehensive SWOT framework.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Global Novel Vaccine Delivery Devices (By Value)  Type of Device Electroporation-based Needle Free Injection Systems Oral Delivery Systems Nasal Delivery Systems Jet Injectors Microneedle Patches Microinjectors  Route of Administration Oral Intramuscular Intranasal Intradermal Subcutaneous  Type of Vaccines Bivalent Oral Polio Vaccine BCG Vaccine DTP-HepB-Hib Vaccine Pneumococcal Conjugate Vaccine Influenza Vaccine Measles Vaccine Tetanus-Diphtheria Vaccine Others  Key Geographical Region  North America  Europe  Asia Pacific  Rest of the World Key companies covered in the report  3M  Becton Dickinson  Consort Medical  D’Antonio Consultants International  Enesi Pharma  Ichor Medical  Iconovo  Inovio Pharmaceuticals  PharmaJet  Union Medico For additional details, please visit https://www.rootsanalysis.com/reports/view_document/vaccine-delivery-devices/280.html or email [email protected] You may also be interested in the following titles: 1. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 2. Subcutaneous Biologics, Technologies and Drug Delivery Systems (2nd Edition), 2018-2030 3. Large Volume Wearable Injectors Market (4th Edition), 2018-2030 4. Global Autoinjectors Market (2nd Edition), 2018-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

The ophthalmic drugs contract manufacturing market is estimated to be worth USD 1.7 billion in 2030, predicts Roots Analysis

https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.” The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:  A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters.  A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations.  Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products.  A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products.  An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain.  An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to ophthalmic drug developers.  A discussion on the emerging trends and potential market drivers, which are likely to impact the evolution of the market in the coming years.  A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on a number of relevant parameters. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of product  Ophthalmic API  Ophthalmic drug FDF  Type of FDF manufactured  Solid  Semi-solid  Liquid / suspension  Type of primary packaging  Ampoule / vial  Glass / plastic bottle  Ointment tube  Blister packing  Other forms  Scale of manufacturing  Clinical  Commercial  Company size  Small  Mid-sized  Large  Very large  Target disease indication  Age-related macular degeneration  Dry eye  Glaucoma  Other disease segments  Key geographical regions  North America (US, Canada and Mexico)  Europe (UK, Germany, France, Spain, Italy and rest of Europe)  Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)  Rest of the world Key companies covered in the report  Akorn  Akums  Bal Pharma  Catalent  Cayman Chemical  Entod Pharmaceuticals  Farmigea  Glenmark Pharmaceuticals  Indiana Ophthalmics  Lomapharm  Medichem  Pillar5 Pharma  Recipharm  Salvat  Sterling Pharmaceutical Services  Sunways India For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html Other Recent Offerings 1. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 2. Pharmaceutical Continuous Manufacturing Market, 2020-2030 3. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected] Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 [email protected] Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/

Addicted to บาคาร่าออนไลน์? Us Too. 6 Reasons We Just Can't Stop

https://penzu.com/p/c48b80c2

เว็บไซต์แทงบอล เป็นความแตกต่างอย่างเห็นได้ชัดในการพนันบอลในอดีตกับปัจจุบันซึ่งเมื่อก่อนกับการพนันบอลกับโต๊ะพนันบอลต่างๆซึ่งจะมีข้อกำหนดอยู่หลายประเภทด้วยกัน และยังเป็นผลเสียโดยตรงต่อนักเสี่ยงโชคบอลทุกคนโดยตรงอีกด้วยไม่ว่าจะเป็นความสิ้นเปลืองค่าครองชีพ

5 Killer Quora Answers on บาคาร่าออนไลน์

http://franciscoilch049.image-perth.org/10-sites-to-help-you-become-an-expert-in-ba-kha-ra-xxnlin

ufabet978 เป็นโอกาสที่ดีสำหรับนักเล่นการพนันทุกคนที่กำลังมองหาหนทางสำหรับการลงทุนให้กับตัวเองกับการทดลองสมัครเข้ามาเป็นสมาชิกกับเว็บพนันออนไลน์ยูฟ่าเบท 978 ซึ่งเป็นช่องทางสำหรับเพื่อการวางเดิมพันกับเกมการเดิมพันออนไลน์ทุกชนิดได้สม่ำเสมอตลอดเวลา